Many hoped the 2013 declaration by the American Medical Association that obesity is a disease would open the door for payer coverage of pharmacotherapy to treat it. While that did not happen right way, a new commentary in Evidence-Based Diabetes Management by Ted Kyle, RPh, MBA, and Fatima Cody Stanford, MD, MPH, MPA, outlines how the tide appears to be turning for coverage of evidence-based treatment.
FOR IMMEDIATE RELEASESeptember 25, 2015
PLAINSBORO, N.J.—At long last, payer coverage for obesity pharmacotherapy appears to be gaining traction, giving physicians and their patients important evidence-based tools to treat obesity, according to a new commentary in Evidence-Based Diabetes Management, a publication of The American Journal of Managed Care.
Co-authors Ted Kyle, RPh, MBA, chairman of the Obesity Action Coalition, and Fatima Cody Stanford, MD, MPH, MPA, a physician in the Massachusetts General Hospital Weight Center and an instructor at Harvard Medical School, discuss how coverage for obesity drugs has varied since the American Medical Association (AMA) declared obesity a disease in their commentary, “Stumbling Toward Access to Evidence-Based Care for the Chronic Disease of Obesity.” While many hoped the AMA declaration in June 2013 would open doors for payer coverage, the authors explain how things have unfolded more slowly, despite the evidence. For the commentary, click here.
Under the Affordable Care Act, they write, “while 23 states classify bariatric surgery as an essential health benefit, only 5 states classify medical obesity treatment as an essential benefit.” The result is that for too many patients, obesity drugs have been unaffordable, limiting treatment options. However, as Kyle and Stanford write, the past year has brought several key shifts:
· In 2014, the AMA resolved to press for patient access to a full spectrum of options, including obesity drugs.
· Also in 2014, rules for federal employee health plans changed to require coverage of obesity therapies.
· The National Conference of Insurance Legislators called on state legislatures to cover “the full range of obesity treatment,” and major pharmacy benefit managers are starting to add drugs to the formulary.
· Bipartisan support is building to add obesity drugs to Medicare Part D.
About the Journals and AJMC.com
The American Journal of Managed Care celebrates its 20th year in 2015 as the leading peer-reviewed journal dedicated to issues in managed care. AJMC.com distributes healthcare news to leading stakeholders across a variety of platforms. Other titles in the franchise include The American Journal of Pharmacy Benefits, which provides pharmacy and formulary decision-makers with information to improve the efficiency and health outcomes in managing pharmaceutical care, and The American Journal of Accountable Care, which publishes research and commentary on innovative healthcare delivery models facilitated by the 2010 Affordable Care Act. AJMC’s Evidence-Based series brings together stakeholder views from payers, providers, policy makers, and pharmaceutical leaders in oncology and diabetes management. To order reprints of articles appearing in AJMC publications, please call (609) 716-7777, x 131.
Contact:
Nicole Beagin
(609) 716-7777 x 131
Patients With Advanced, Recurrent Melanoma May Experience Lasting AEs From ICM Therapy
May 9th 2024A cross-sectional, mixed-methods study found that adverse effects (AEs) can occur even after 1 year of treatment with immune checkpoint modulator (ICM) therapy in patients with melanoma.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Goal Achievement in T1D Management Boosts Self-Efficacy, Self-Care Among Emerging Adults
May 9th 2024Findings from the FAMS-T1D study demonstrate that structured goal-setting and achievement significantly enhance self-efficacy and self-care in emerging adults who have type 1 diabetes (T1D).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Integrating RECIST and Clinician Approaches Boosts NSCLC Research
May 8th 2024Outcomes among patients with stage IV non–small cell lung cancer as evaluated within clinical trials via Response Evaluation Criteria in Solid Tumors (RECIST) and clinician response criteria in observational studies were compared for their concordance and reliability.
Read More